Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among persons with type 2 diabetes. The effect of an exendin-based GLP-1 receptor agonist, efpeglenatide, on cardiovascular and renal outcomes in patients with type 2 diabetes who are also at high risk for adverse cardiovascular events is uncertain. METHODS: of body-surface area) plus at least one other cardiovascular risk factor. Participants were randomly assigned in a 1:1:1 ratio to receive weekly subcutaneous injections of efpeglenatide at a dose of 4 or 6 mg or placebo. Randomization was stratified according to use of sodium-glucose cotransporter 2 inhibitors. The primary outcome was the first major adverse cardiovascular event (MACE; a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular or undetermined causes). RESULTS: A total of 4076 participants were enrolled; 2717 were assigned to receive efpeglenatide and 1359 to receive placebo. During a median follow-up of 1.81 years, an incident MACE occurred in 189 participants (7.0%) assigned to receive efpeglenatide (3.9 events per 100 person-years) and 125 participants (9.2%) assigned to receive placebo (5.3 events per 100 person-years) (hazard ratio, 0.73; 95% confidence interval [CI], 0.58 to 0.92; P<0.001 for noninferiority; P = 0.007 for superiority). A composite renal outcome event (a decrease in kidney function or macroalbuminuria) occurred in 353 participants (13.0%) assigned to receive efpeglenatide and in 250 participants (18.4%) assigned to receive placebo (hazard ratio, 0.68; 95% CI, 0.57 to 0.79; P<0.001). Diarrhea, constipation, nausea, vomiting, or bloating occurred more frequently with efpeglenatide than with placebo. CONCLUSIONS: In this trial involving participants with type 2 diabetes who had either a history of cardiovascular disease or current kidney disease plus at least one other cardiovascular risk factor, the risk of cardiovascular events was lower among those who received weekly subcutaneous injections of efpeglenatide at a dose of 4 or 6 mg than among those who received placebo. (Funded by Sanofi; AMPLITUDE-O ClinicalTrials.gov number, NCT03496298.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The effects of semaglutide on albuminuria and eGFR observed in the present STEP analysis are consistent with post hoc analyses of other GLP-1RA clinical trials.”
From Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials (2023) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most GLP-1 RAs had a neutral effect on risk of HF hospitalization in the placebo-controlled RCTs assessing CV safety of glucose-lowering medications in patients with T2DM with or at high risk of ASCVD, despite increasing heart rate by 3-5 b.p.m. 70,72,158- 163,544”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [163]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging data suggest that use of both classes of drugs will provide an additive cardiovascular and kidney outcomes benefit;”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [270]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Over a median follow-up of 1.8 years, efpeglenatide therapy reduced the risk of incident major adverse cardiovascular events by 27% and of a composite renal outcome event by 32%.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [214]
The cited source says what the claim attributes to it.
In the citing paper
“Some GLP-1RAs [albiglutide, efpeglenatide, dulaglutide, liraglutide and once-weekly (OW) semaglutide] reduce the risk of major adverse CV events (MACE) in people with T2D with established CVD or at high risk of CVD [6][7][8][9][10].”
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
Self-citationKristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Self-citationType 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people
Shah, A. D., Langenberg, C., Rapsomaniki, E., Denaxas, S., Pujades-Rodriguez, M., Gale, C. P., Deanfield, J., Smeeth, L., Timmis, A., & Hemingway, H. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70219-0 · Cited by 1,225
Association of cardiometabolic multimorbidity with mortality
Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., Butterworth, A. S., Bansal, N., O’Keeffe, L. M., Gao, P., Wood, A. M., Burgess, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.7008 · Cited by 1,155
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes
Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008121270 · Cited by 965
Matsushita, K., Coresh, J., Sang, Y., Chalmers, J., Fox, C., Guallar, E., Jafar, T., Jassal, S. K., Landman, G. W. D., Muntner, P., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00040-6 · Cited by 903
The Global Epidemiology of Diabetes and Kidney Disease
Koye, D. N., Magliano, D. J., Nelson, R. G., & Pavkov, M. E. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.10.011 · Cited by 686
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638
Self-citationLaiteerapong, N., Ham, S. A., Gao, Y., Moffet, H. H., Liu, J. Y., Huang, E. S., & Karter, A. J. (2019) · Diabetes Care · doi:10.2337/dc17-1144 · Cited by 574
Cited by
Items 801–873 of 873
Ternhamar, T., Johansen, M. Ø., Nordestgaard, B. G., & Afzal, S. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03242-9
Ramadan, A., Aglan, A., Salama, B., Abdalla, M., Fath, A., Frishman, W. H., & Aronow, W. S. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001322
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
Stratégies thérapeutiques dans le traitement du diabète de type 2
Bordier, L., & Bauduceau, B. (2026) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(25)49531-6
Zeng, B., Hsu, C.-W., Hung, C., Yang, W.-C., Stubbs, B., Chen, Y.-W., Lei, W.-T., Chen, J.-J., Chen, T., Hsu, S., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104026
Les traitements du diabète de type 2 : les preuves
Bordier, L., & Bauduceau, B. (2026) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2026.100822
Godínez, E. F., Arriaga-Cázares, H. E., Villagrán, G. A., Lucas, C. P., Pérez, J. A. P., Padilla, F. J. T., Clemente, A., & Mondragón, S. M. (2026) · IECCMEXICO · doi:10.64784/226
Mohammadi, D., Sadeghirad, B., Rasouli, M. A., Saed, L., Baradaran, H. R., & Moradi, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02226-9
Abdalla, S. A. M., Mohammed, H. O. A., Omer, E. O. E., Ahmed, I. O. I., Ahmed, W. A. O., Ginawi, K. O. T., Abdelfattah, R. E. M., Yousif, A. A. Z., & Ismail, K. I. A. (2026) · Cureus · doi:10.7759/cureus.111723
Algazzar, A. S. (2026) · Saudi Journal of Internal Medicine · doi:10.4103/sjim.sjim_12_26
Jafar, T. H., Zhu, A., & Ogungbe, O. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001173
Raaschou-Pedersen, D. E. T., Andreasen, C. R., Kovalova, T., Branch, K. R., Prato, S. D., Lam, C. S. P., Lópes, R. D., Pratley, R. E., Rosenstock, J., Sattar, N. A., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71062
Self-citationSzerenos, N., Woroniecka, N., Trocka, D., Kozłowska, A., Przybysz, K., Stadnik, L., Zienkiewicz, N., Rachoń, J., Dzwonkowska, A., & Dzwonkowski, J. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6150
Dey, S., Saha, S., Mandal, D., Maity, R., Mir, U. B., Chowdhury, S. R., Kundu, S., & Saha, L. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.62s.99
Chae, H. H., Luo, C., Harriman, D. I., & Nguan, C. (2026) · Canadian Urological Association Journal · doi:10.5489/cuaj.9689
Sun, W.-T., Liu, R., Jiang, Y.-H., Zhao, Y., Yi‐Cai, Wu, Y. T., Li, T., & Chang, P. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71094 · Cited by 1
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.032
Rapidly changing landscape of diabetic kidney disease management: recent advances and the road ahead
Wang, S. S. Y., Chan, Y. Z., Luo, X. R., Tan, N. A. M. R., Klein, M., & Javaid, M. M. (2026) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-240
Liu, P.-Y., Shih, C.-K., Hsieh, M. H., Lin, C., Liu, C. L., Lai, E. C., Li, C., Yu, C.-H., & Sung, J. (2026) · Nature Communications · doi:10.1038/s41467-026-76083-5
Peptide‐Based GLP‐1 Receptor Agonists for the Treatment of Type 2 Diabetes and Obesity
Kodra, J. T., Linderoth, L., Reedtz‐Runge, S., Kruse, T., & Kofoed, J. (2026) · Wiley eBooks · doi:10.1002/9783527845408.ch4
Liang, Y., Li, C., Huang, B., Wang, A., Qiu, M., Lu, J., & Wan, J. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2707003
Mazzola, A., Sultanik, P., Rebiha, A., Pais, R., Thabut, D., Scatton, O., Bourron, O., & Conti, F. (2026) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2026.102899
ПЛЕЙОТРОПНЫЕ ЭФФЕКТЫ АГОНИСТОВ РЕЦЕПТОРОВ ГЛЮКАГОНОПОДОБНОГО ПЕПТИДА‑1
Юрьевич, Ц. В., Lazareva, I. A., Владимировна, Б. Н., Полякова, О. В., & Николаевна, У. С. (2026) · Современные проблемы науки и образования · doi:10.17513/spno.34690
Kim, J., Jeon, J., Yoo, J., Baik, M., Heo, S., & Roh, J. W. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70385
Chen, Y., & Chen, S. C. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02266-1
Estrategias nutracéuticas dirigidas a la unidad neurovascular en la retinopatía diabética
Fragiotta, S., Ciancimino, C., & Scuderi, G. (2026) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2026.502655
Mazzone, P. M., Giacoppo, D., Ammirabile, N., Mauro, M. S., Spagna, F., & Capodanno, D. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag430
Grenet, G., Eskandari, R., Ko, J., Adams, S. P., Salzwedel, D. M., Heran, B. S., Ambasta, A., Bassett, K., & Thompson, W. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2026-006225
Macía-Heras, M., Hernández-Marrero, D. J., Martínez‐Alberto, C. E., Siverio-Morales, O., & Donate‐Correa, J. (2026) · BMC Nephrology · doi:10.1186/s12882-026-05304-2
Ahsan, M., Mazhar, S., Zafar, H., Mansoor, H., Nancy, F., Abbas, S. M., Shaikh, H., Khan, D. Z., Khan, A., Zahoor, B., et al. (2026) · Comprehensive physiology · doi:10.1002/cph4.70246
Alshammeri, O., Alshehri, H. Z., AlSaif, S. M., Alasnag, M. A., Qaddoura, F., Alqahtani, F., Turkistani, Y., Alharbi, W., Tash, A. A., Alshehri, M., et al. (2026) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1516
Neurovascular unit-targeted therapeutic strategies in diabetic retinopathy
Fragiotta, S., Ciancimino, C., & Scuderi, G. (2026) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2026.502655
Emerging therapies for diabetic kidney disease: beyond SGLT2 inhibitors
Ni, H., Piggott, S., Festa, M. C., Faruque, L. I., & Cherney, D. Z. I. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2723583
Shirmohamadi, E., Ghasemloo, N., Ebrahimi, N., Mohammadzadeh, N., Ehtemami, A., Babaei, M., & Fardoost, S. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70311
Elsayed, A., Ayoub, W. J., ELSAYED, N., Stephens, J. P., Udongwo, N., Elsayed, Y. A.-E., & Ghali, J. K. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00322-3
Gisal, M., Koźlak, J., Sokół, M., Wróblewska, K., Leszczyński, F., & Stopyra, L. (2026) · Journal of Pre-Clinical and Clinical Research · doi:10.26444/jpccr/235860
Zhao, X., & Zhou, Y. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100540
Sun, D., Wang, X., Wang, H., Shen, Z., Meng, X., & Zhou, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1933732
Fan, Y., Peng, N., Jiang, L., Wei, R., Lu, G., Zhang, S., Mu, C., Xue, M., Lyu, B., & Yao, D. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71313
Li, M. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1926629
Nassiri, S., Handoko, M. L., van de Bovenkamp, A. A., van Empel, V. P. M., van Raalte, D. H., & Eringa, E. C. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10671-x
GLP-1 Receptor Agonists, Stroke, and Cognitive Outcomes: Systematic Review and Meta-RegressionPreprint
Danielli, M., Sibal, R., Collett, G., Awan, H., Sharma, C., Steckelmacher, J., Kennedy, C., & Gupta, A. K. (2026) · medRxiv · doi:10.64898/2026.09.18.26363449
Inzucchi, S. E. (2026) · Diabetes Care · doi:10.2337/dci26-0047
O IMPACTO DOS AGONISTAS DO GLP-1 NA REDUÇÃO DO RISCO CARDIOVASCULAR EM PACIENTES COM DIABETES TIPO 2
Felippe, N. F., Fernandes, A. B. L., & Bernardelli, L. R. (2026) · Editora Pasteur eBooks · doi:10.59290/6200141930
Advances in weight-loss-independent cardiovascular protective mechanisms of GLP-1 receptor agonists
Ma, J., Feng, X., Xu, W., & Lyu, J. (2026) · Peptides · doi:10.1016/j.peptides.2026.171519
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
Yuan, Y., Chen, C., Li, X., Guo, J., Liu, Q., Lin, Y., Sun, L., & Fan, G. (2026) · Drugs · doi:10.1007/s40265-026-02380-4
Salim, H., Qureshi, S., Gulsin, G. S., Khan, H. R., Waqas, S. A., McCann, G. P., Garg, A., Shurrab, M., Khunti, K., & Rashid, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71375
Pedagogos, E., Chen, R., Nelson, A. J., Badve, S. V., Rasalam, R. R., & MacIsaac, R. J. (2026) · Internal Medicine Journal · doi:10.1111/imj.70647
Li, Q., Yang, T., Jin, G., & Zhou, Y. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1930278
GLP-1 receptor agonists—a potential therapy for chronic kidney disease?
Boeckhaus, J., Sayer, J. A., & Mabillard, H. R. (2026) · Clinical Science · doi:10.1042/cs20261312
GLP-1 receptor agonists in cardiometabolic disease: a meta-analysis of 102,486 patients
Alwaily, Z. A., Rahman, O. U., Swe, A. T., Abouayana, A., Sodhi, N. S., Goh, M. J., Ahmed, A., Natesan, T. A., Shahzad, S., Merchant, O. H., et al. (2026) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/226416
Mauriello, A., Cetoretta, V., Giudice, C. D., Correra, A., Maratea, A. C., Gioia, R., Liccardo, B., Esposito, G., Russo, V., & D’Andrea, A. (2026) · Biomedicines · doi:10.3390/biomedicines14102257
Alkhalidi, Z. N., Jafaar, A. M., Ismail, H. K., Alkhalidi, M. N., Arif, S. F., Jaf, S. M., Omar, S. S., & Ali, S. H. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02747-4
Pathway-guided and patient-centred therapeutic strategies in atherosclerotic cardiovascular disease
Canonico, M. E., Avvedimento, M., Borrelli, F., Giugliano, G., Gargiulo, G., Piccolo, R., Stabile, E., Mestroni, L., Taylor, M. R. G., Chen, S. N., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag523
GLP‐1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications
Ueda, P. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70170
Bashir, M. B., Chen, C., Alzghool, M., Ahmed, R. M., & Wang, Z. (2026) · Scientific Reports · doi:10.1038/s41598-026-73850-8
Kierzkowski, F., Skrzypek, W., Bryl, W., Paczkowska, A., & Hoffmann, K. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1977433
Ischémie myocardique silencieuse
Spagnoli, V. (2026) · EMC - Cardiologie · doi:10.1016/s1166-4568(25)49484-4
Young, C. F., George, N., Olson, A., & Diana, I. (2026) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2026.22.2.3
Berikkhanova, K., Inuwa, I., Sultan, Y., Berikkhanov, N., Rakhimova, S., & Akilzhanova, A. R. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15208190
Abdulla, F. I., Alqahtani, A. A., & Sait, N. S. (2026) · SAS Journal of Medicine · doi:10.36347/sasjm.2026.v12i10.014
Saleem, M. F., Mansoor, A., Shahid, E., Lohana, M., Ghafoor, M. S., Khan, M. U., Abbas, F. M., Hirpara, H., Khalid, A., Hassan, F., et al. (2026) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2026.3980
Seo, Y., & Woo, J. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104843
Fujii, A., Hasebe, M., Furuichi, K., Yabe, D., & Yoshiji, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71496
Vashisht, R., Dhruva, S. S., Patel, A., Dahm, L., Morris, P., Gonzalez, D. M., Follett, R., Sirota, M., Singh, K., Koliwad, S. K., et al. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261498914
Velasco, M. Á. P., Trenas, A., Padilla-Leiva, C., Pérez-Ruiz, J. M., Ruíz-Rodríguez, F. I., Gómez-Huelgas, R., Bernal-López, M. R., & Perez-Belmonte, L. M. (2026) · Medicina Clínica · doi:10.1016/j.medcli.2026.107663
Chotalia, R., Ghias, O., Shah, M. U., Hills, C. E., Ward, J. K., Squires, P. E., Andrews, R., Venugopal, V., Lee, K., & Gulsin, G. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2757946
Blontrock, E., Oyaert, M., Ikawaty, R., Cahyono, A., Delrue, C., & Speeckaert, M. M. (2026) · Diagnostics · doi:10.3390/diagnostics16213645
Skelin, M., Perkov-Stipičin, B., Bračić, V., Škugor, Z., & Krečak, I. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71511
Wang, Z., Zhang, P., Zhang, Y., & Bai, J. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113638
Genetically-proxied GLP1R agonism and cardiometabolic outcomes in East Asian Biobank populations
Tinworth, A. C., Koyama, S., Belbasis, L., Valdés‐Márquez, E., Ito, K., Matsuda, K., Gajendragadkar, P. R., Yu, C., Sun, D., Pei, P., et al. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1954956
Metadata
- Authors
- Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., Dyal, L., & Branch, K.
- Affiliations
- University of Pisa (IT)
- From the Population Health Research Institute, Hamilton Health Sciences (H.C.G., C.R., L.H., L.D.), and McMaster University (H.C.G.) — both in Hamilton, ON, Canada; the Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (N.S.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); AdventHealth Translational Research Institute, Orlando, FL (R.P.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.); National Heart Centre Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); Sanofi, Bridgewater, NJ (N.S.K.); the Section of Metabolic Diseases and Diabetes, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy (S.D.P.); and the Division of Cardiology, University of Washington, Seattle (K.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-02
- Volume
- 385
- Issue
- 10
- Pages
- 896-907
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177365549
- Cited by
- 829
- References
- 29
- Citations by year
- 2026: 150 · 2025: 187 · 2024: 159 · 2023: 149 · 2022: 136 · 2021: 47
- FWCI
- 91.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- efpeglenatide, type 2 diabetes, GLP-1 receptor agonists, exendin-4, major adverse cardiovascular events, cardiovascular risk, renal outcomes, renal function decline, macroalbuminuria, SGLT2 inhibitors, gastrointestinal adverse effects, non-inferiority, cardiovascular disease history, kidney disease, cardiovascular risk factors, myocardial infarction
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Heart Disease Risk Factors, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Kidney Diseases, Male, Middle Aged, Proline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
